Intentar ORO - Gratis

US withdrawal a setback for global efforts: ReNew CEO

Business Standard

|

January 12, 2026

ReNew Chairman and Chief Executive Officer Sumant Sinha says he believes the latest US withdrawal from global organisations working to address climate change is a setback.

US withdrawal a setback for global efforts: ReNew CEO

Q&A The Indian industry is also in talks with the government on demands for compensation for revenue losses due to delays in transmission capacity creation, while the production-linked incentive (PLI) scheme for renewable energy has seen limited uptake, he tells Sudheer Pal Singh in an interview in New Delhi. Edited excerpts:

What do you make of the latest US withdrawal from 66 global organisations working to address climate change?

That list includes the United Nations Framework Convention on Climate Change, the International Renewable Energy Agency, and the International Solar Alliance.

It was on the cards for a long time and had already been baked into people’s expectations. This has been the stated position of the current US administration for a while, and everyone knew it was coming. The US did not show up at the Conference of the Parties (COP). It had, de facto, already pulled out of these institutions. Now it has done so more formally —that’s all.

What would be its impact?

When the world’s largest economy pulls out of anything, it is clearly a setback. It is a setback for climate action, including the scientific work underpinning climate change studies. Several research and measurement organisations in the US have seen their funding cut.

The benefit of climate research already carried out in the US will no longer be available. When the largest economy pulls out and does not do enough to curb its carbon emissions, it weakens global efforts.

‘The silver lining is that COP still happened, and the other 192 countries reaffirmed their commitment to tackling climate change.

MÁS HISTORIAS DE Business Standard

Business Standard

Labour Codes impact: HCL tech profit slips 11%

Q3 top line beats Street estimates, bottom line misses expectations

time to read

2 mins

January 13, 2026

Business Standard

New labour Codes, restructuring weigh on TCS earnings

Tata Consultancy Services (TCS), India’s largest information technology (IT) services firm, saw its profit impacted in the October-December quarter by restructuring and changes in labour Codes.

time to read

1 min

January 13, 2026

Business Standard

Business Standard

Black drives the thrill for car buyers

Sees a surge in yearly sales, while white remains practical 'utility king'

time to read

2 mins

January 13, 2026

Business Standard

CHOOSING THE RIGHT B-SCHOOL TO MATCH YOUR CAREER GOALS

Success comes when you pick an institution that fits your professional dreams and your personality, helping you become the leader you want to be

time to read

2 mins

January 13, 2026

Business Standard

Business Standard

China’s PVC rethink to help India pipe makers

Supply likely to tighten after S-PVC rebate withdrawal

time to read

2 mins

January 13, 2026

Business Standard

Responsible growth

India must ensure data centres are sustainable

time to read

2 mins

January 13, 2026

Business Standard

India’s GenZ is full of creativity: PM

Prime Minister Narendra Modi on Monday said India's GenZ is full of creativity and with innovative ideas, energy and purpose, the country’s youth is at the forefront of nation-building.

time to read

1 min

January 13, 2026

Business Standard

Business Standard

Iran wants to negotiate after threats to attack, says Trump

At least 572 killed in protests; Tehran says situation ‘under full control’

time to read

2 mins

January 13, 2026

Business Standard

Insurers knock on Irdai door for clarity on director overlap ban

CLAUSE THREATENS BOARD STRUCTURES AT BANK-BACKED FIRMS SAYS INDUSTRY

time to read

2 mins

January 13, 2026

Business Standard

Delhi HC allows Zydus to sell generic version of cancer drug

Citing public interest, the Delhi High Court has cleared the way for Zydus Life-sciences to proceed with the sale of its version of the cancer drug nivolumab in India.

time to read

1 min

January 13, 2026

Listen

Translate

Share

-
+

Change font size